Key Insights

Highlights

Treatment Research

4 treatments under study, led by Bevacizumab Avastin Genentech Inc

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Not Yet Recruiting2
Withdrawn1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07681167Phase 2Not Yet RecruitingPrimary

Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial

NCT07347119Not Yet RecruitingPrimary

Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients

NCT01256580Not ApplicableWithdrawn

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

Showing all 3 trials

Research Network

Common Treatments

  • Bevacizumab Avastin Genentech Inc1
  • Bevacizumab Dexamethasone Verteporfin Photodynamic Therapy1
  • Sham1
  • Faricimab1

Active Sponsors

  • Roche1
  • Massachusetts Eye and Ear Infirmary1
  • Singapore National Eye Centre1
  • Sun Yat-sen University1

Top Investigators

Related Conditions

  • Myopia1
  • Punctate Inner Choroidopathy Pic1
  • Multifocal Choroiditis1
  • Choroidal Neovascularization1
  • Ocular Histoplasmosis Syndrome1

Activity Timeline